Treatment Information

Back

Brain – Glioblastoma Multiforme treatment details. Chemotherapy, Radiation.

UAB Department of Neurology , Birmingham, AL, United States.

Survival: monthsCountry:United States
Toxiciy Grade:5City/State/Province:Birmingham, AL
Treatments:Chemotherapy, RadiationHospital:UAB Department of Neurology
Drugs:Journal:Link
Date:May 2015

Description:

Patients:
This phase 2 study involved unmethylated MGMT gene promoter glioblastoma patients who were divided into two separate treatment groups. Group A had 88 patients with a median age of 55.6 years and 56.8% male. Group B had 89 patients with a median age of 57.7 years and 61.8% were male.

Treatment:
Patients in group A received radiation therapy and chemotherapy with temozolomide and cilengitide.

Patients in group B received radiation therapy and chemotherapy with temozolomide.

Toxicities:
There were two treatment-related deaths in group A due to thrombocytopenia and pulmonary embolism. Grade 3 or higher lymphopenia, muscular weakness, and rash were also reported.

One treatment-related death due to pancytopenia (decreased numbers of all types of blood cells) was reported in group B. Grade 3 or higher weakness and deep vein thrombosis were also reported.

Results:
The median overall survival times for groups A and B were 16.3 and 13.4 months, respectively.

Support:
This study was supported by Merck.

Correspondence: Dr. Louis Burt Nabors; email: bnabors@uab.edu



Back